Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    

INC RESEARCH HOLDINGS INC
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Rosen Law Firm Announces Investigation of Securities Claims Against INC Research Holdings, Inc. – INCR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:04pm CEST

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) resulting from allegations that INC Research may have issued materially misleading business information to the investing public.

On August 1, 2017, INC Research and inVentiv Health, Inc. (“inVentiv Health”) announced the completion of a merger between the two companies. On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. On this news, shares of INC Research fell $16.35 per share or over 28% from its previous closing price to close at $41.15 per share on November 9, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by INC Research investors. If you purchased shares of INC Research, please visit the firm’s website at http://www.rosenlegal.com/cases-1236.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
04/20SYNEOS HEALTH : Schedules First Quarter 2018 Earnings Call for Wednesday May 9 2..
AQ
04/17Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9..
GL
04/13SYNEOS HEALTH : Capri EGM Provides Build-to-Suit Financing and Announces Acquisi..
AQ
04/04INC. (NASDAQ : INCR) Files An 8-K Other Events
AQ
04/04INC. (NASDAQ : INCR) Files An 8-K Departure of Directors or Certain Officers; El..
AQ
03/30SYNEOS HEALTH : Helps Establish New Industry Standards Group to Improve Clinical..
AQ
03/28SYNEOS HEALTH : Helps Establish New Industry Standards Group to Improve Clinical..
AQ
03/27Syneos Health Helps Establish New Industry Standards Group to Improve Clinica..
GL
03/23SYNEOS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
03/20KNOW IN-DEPTH ABOUT CONTRACT RESEARC : Contract Research Organizations (CRO) Ser..
AQ
More news
News from SeekingAlpha
01/03INC Research CFO exiting post at April's end 
2017INC Research Holdings 2017 Q3 - Results - Earnings Call Slides 
2017INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca.. 
2017Midday Gainers / Losers 
2017INC Research misses by $0.08, misses on revenue 
Financials ($)
Sales 2018 4 427 M
EBIT 2018 518 M
Net income 2018 57,2 M
Debt 2018 2 871 M
Yield 2018 -
P/E ratio 2018 70,28
P/E ratio 2019 26,54
EV / Sales 2018 1,55x
EV / Sales 2019 1,41x
Capitalization 3 985 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | US45329R1095 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 50,6 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Alistair Macdonald Chief Executive Officer
Michael A. Bell Chairman
Jason M. Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Director
Purvesh Patel Secretary & Chief Administrative Officer
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-5.39%3 985
CELLTRION, INC.--.--%29 110
IQVIA HOLDINGS INC-1.44%20 148
LONZA GROUP-9.23%18 502
NEKTAR THERAPEUTICS38.30%13 600
INCYTE CORPORATION-34.17%13 206